TACIMA-218: A Novel Pro-Oxidant Agent Exhibiting Selective Antitumoral Activity
Jamilah Abusarah1, Yun Cui2, Nehme El-Hachem3,4
1The Department of Microbiology and Immunology, McGill University, Montréal, Québec, Canada.
Abstract:
We report the discovery, via a unique high-throughput screening strategy, of a novel bioactive anticancer compound: Thiol Alkylating Compound Inducing Massive Apoptosis (TACIMA)-218. We demonstrate that this molecule engenders apoptotic cell death in genetically diverse murine and human cancer cell lines, irrespective of their p53 status, while sparing normal cells. TACIMA-218 causes oxidative stress in the absence of protective antioxidants normally induced by Nuclear factor erythroid 2-related factor 2 activation. As such, TACIMA-218 represses RNA translation and triggers cell signaling cascade alterations in AKT, p38, and JNK pathways. In addition, TACIMA-218 manifests thiol-alkylating properties resulting in the disruption of redox homeostasis along with key metabolic pathways. When administered to immunocompetent animals as a monotherapy, TACIMA-218 has no apparent toxicity and induces complete regression of pre-established lymphoma and melanoma tumors. In sum, TACIMA-218 is a potent oxidative stress inducer capable of selective cancer cell targeting.
Insights
Researchers discovered a novel anticancer compound, TACIMA-218, that selectively targets cancer cells by inducing oxidative stress and apoptosis. This compound shows promise as a potent therapeutic agent with no apparent toxicity in preclinical models.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Development of novel anticancer agents with selective toxicity is crucial.
- Targeting cancer cell-specific vulnerabilities, such as redox homeostasis, is a promising strategy.
- Nuclear factor erythroid 2-related factor 2 (Nrf2) pathway activation confers resistance to oxidative stress in cancer cells.
Purpose of the Study:
- To report the discovery and characterization of a novel bioactive anticancer compound, TACIMA-218.
- To investigate the mechanism of action of TACIMA-218, including its effects on oxidative stress, cell signaling, and metabolism.
- To evaluate the in vivo efficacy and toxicity of TACIMA-218 as a monotherapy.
Main Methods:
- High-throughput screening strategy for identifying novel bioactive compounds.
- In vitro studies using diverse murine and human cancer cell lines and normal cells.
- Assessment of oxidative stress, RNA translation, cell signaling pathways (AKT, p38, JNK), and redox homeostasis.
- In vivo studies in immunocompetent animals with pre-established lymphoma and melanoma tumors.
Main Results:
- TACIMA-218 induces apoptotic cell death in various cancer cell lines, irrespective of p53 status, while sparing normal cells.
- TACIMA-218 acts as an oxidative stress inducer by inhibiting Nrf2-mediated antioxidant responses.
- TACIMA-218 represses RNA translation, alters AKT, p38, and JNK signaling, and disrupts redox homeostasis and metabolic pathways.
- In vivo administration of TACIMA-218 as monotherapy leads to complete regression of lymphoma and melanoma tumors without apparent toxicity.
Conclusions:
- TACIMA-218 is a novel thiol-alkylating compound with potent anticancer activity.
- Its mechanism involves selective induction of oxidative stress, leading to cancer cell apoptosis.
- TACIMA-218 demonstrates significant therapeutic potential as a targeted anticancer agent.
